Summary
The linearity of the pharmacokinetics of the metamizol metabolites 4-methyl-amino-antipyrine (4-MAA), 4-amino-antipyrine (4-AA), 4-formyl-aminoantipyrine (4-FAA), and 4-acetyl-amino-antipyrine (4-AcAA) has been studied after administration to 15 healthy male volunteers of single oral doses of 750, 1500, and 3000 mg metamizol. The trial was open, randomized, and cross-over, with a one-week interval between dosing days. Metabolite concentrations in serum and urine were measured using reverse-phase HPLC.
The mean Cmax of 4-MAA increased linearly with dose whereas its AUC was not proportional to dose after administration of 1500 and 3000 mg.
With 4-AA, the increase in mean Cmax was linear, but the increase in AUC was not.
The increases in mean Cmax and AUC for 4-FAA after doses of 1500 and 3000 mg were not proportional to the dose.
The increases in mean Cmax and AUC for 4-AcAA were roughly proportional to the increase in dose.
There were no significant differences in renal clearance between doses for any of the four metabolites.
The observed non-linearities reflect the saturability of metabolic pathways. However, although they were statistically significant, the deviations from linearity were marginal and should not be of clinical relevance to the analgesic efficacy of metamizol in the dose range tested.
Similar content being viewed by others
References
Christ O, Kellner HM, Ross G, Rupp W, Schwarz A (1973) Biopharmazeutische und pharmakokinetische Untersuchungen nach Gabe von Metamizol 14C an Ratte, Hund und Mensch. Arzneimittelforschung 23: 1760–1767
Badian M, Eckert H (1986) Kinetics of radiolabelled dipyrone (metamizole) after oral and intravenous administration to healthy men. III World Conference on Clinical Pharmacology and Therapeutics, Stockholm, 1986, Abstract 1591
Weiss R, Brauer J, Goertz U, Petry R (1974) Vergleichende Untersuchungen zur Frage der Absorption und Metabolisierung nach Pyrazolonderivates Metamizol nach oraler Gabe beim Menschen. Arzneimittelforschung 24: 345–348
Volz M, Kellner H-M (1980) Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 10: 299S-308S
Igushi S, Goromaru T, Noda A (1975) A new metabolite of aminopyrine (aminophenazone) in man, 4-formyl-aminoantipyrine. Chem Pharm Bull 23: 932–934
Levy M, Flusser D, Zylber-Katz E, Granit L (1984) Plasma kinetics of dipyrone metabolites in rapid and slow acetylators. Eur J Clin Pharmacol 27: 453–458
Damm D (1989) Simultaneous determination of the main metabolites of dipyrone by HPLC. Arzneimittelforschung 39: 1415–1417
Stoer J (1976) Einführung in die numerische Mathematik. Springer, Berlin Heidelberg New York, S 175–194
Clayton DG (1971) Gram-Schmidt orthogonalization. Appl Stat 20: 335–338
von Hattingberg HM, Brockmeier D (1979) Standardisierung von Rechenmodellen zur Prüfung der Bioverfügbarkeit. In: Rietbrock N, Schnieders B (eds) Bioverfügbarkeit von Arzneimitteln. Fischer, Stuttgart, S 191–209
Brockmeier D (1986) Model-free evaluation and mean-time concept in pharmacokinetics. Meth Find Exp Clin Pharmacol 8: 593–602
Aronson JK, Dengler HJ, Dettli L, Follath F (1988) Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 35: 1–7
Brockmeier D (1984) In vitro-in vivo correlation, a time scaling problem? Arzneimittelforschung 11: 1604–1607
Zylber-Katz E, Granit L, Levy M (1984) Plasma protein binding of dipyrone metabolites in man. Eur J Clin Pharmacol 29: 67–71
Neddermann E, Rohdewald P (1988) Dose-dependent pharmacokinetics of metabolites of dipyrone in saliva. Eur J Drug Metab Pharmacokinet 13: 105–111
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vlahov, V., Badian, M., Verho, M. et al. Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium. Eur J Clin Pharmacol 38, 61–65 (1990). https://doi.org/10.1007/BF00314805
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314805